Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression.

Takeda S, Chen DY, Westergard TD, Fisher JK, Rubens JA, Sasagawa S, Kan JT, Korsmeyer SJ, Cheng EH, Hsieh JJ.

Genes Dev. 2006 Sep 1;20(17):2397-409.

2.

Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis.

Dong Y, Van Tine BA, Oyama T, Wang PI, Cheng EH, Hsieh JJ.

Cell Res. 2014 Nov;24(11):1354-66. doi: 10.1038/cr.2014.129. Epub 2014 Sep 30.

3.

Unraveling the Activation Mechanism of Taspase1 which Controls the Oncogenic AF4-MLL Fusion Protein.

Sabiani S, Geppert T, Engelbrecht C, Kowarz E, Schneider G, Marschalek R.

EBioMedicine. 2015 Apr 16;2(5):386-95. doi: 10.1016/j.ebiom.2015.04.009. eCollection 2015 May.

4.

Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression.

Hsieh JJ, Cheng EH, Korsmeyer SJ.

Cell. 2003 Oct 31;115(3):293-303.

5.

Biphasic MLL takes helm at cell cycle control: implications in human mixed lineage leukemia.

Liu H, Takeda S, Cheng EH, Hsieh JJ.

Cell Cycle. 2008 Feb 15;7(4):428-35. Epub 2007 Dec 6. Review.

PMID:
18235233
6.

The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.

Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML.

Cell. 2005 Oct 21;123(2):207-18.

7.

Overexpression of the catalytically impaired Taspase1 T234V or Taspase1 D233A variants does not have a dominant negative effect in T(4;11) leukemia cells.

Bier C, Hecht R, Kunst L, Scheiding S, Wünsch D, Goesswein D, Schneider G, Krämer OH, Knauer SK, Stauber RH.

PLoS One. 2012;7(5):e34142. doi: 10.1371/journal.pone.0034142. Epub 2012 May 3.

8.
9.

Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis.

Chen DY, Liu H, Takeda S, Tu HC, Sasagawa S, Van Tine BA, Lu D, Cheng EH, Hsieh JJ.

Cancer Res. 2010 Jul 1;70(13):5358-67. doi: 10.1158/0008-5472.CAN-10-0027. Epub 2010 Jun 1.

10.

Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll.

Terranova R, Agherbi H, Boned A, Meresse S, Djabali M.

Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6629-34. Epub 2006 Apr 17.

11.

Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2.

Bach C, Mueller D, Buhl S, Garcia-Cuellar MP, Slany RK.

Oncogene. 2009 Feb 12;28(6):815-23. doi: 10.1038/onc.2008.443. Epub 2008 Dec 8.

PMID:
19060922
12.

Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark.

Revenko AS, Kalashnikova EV, Gemo AT, Zou JX, Chen HW.

Mol Cell Biol. 2010 Nov;30(22):5260-72. doi: 10.1128/MCB.00484-10. Epub 2010 Sep 20.

13.

Cleavage of TFIIA by Taspase1 activates TRF2-specified mammalian male germ cell programs.

Oyama T, Sasagawa S, Takeda S, Hess RA, Lieberman PM, Cheng EH, Hsieh JJ.

Dev Cell. 2013 Oct 28;27(2):188-200. doi: 10.1016/j.devcel.2013.09.025.

14.

The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10.

DiMartino JF, Ayton PM, Chen EH, Naftzger CC, Young BD, Cleary ML.

Blood. 2002 May 15;99(10):3780-5.

15.

Mixed-lineage-leukemia (MLL) fusion protein collaborates with Ras to induce acute leukemia through aberrant Hox expression and Raf activation.

Ono R, Kumagai H, Nakajima H, Hishiya A, Taki T, Horikawa K, Takatsu K, Satoh T, Hayashi Y, Kitamura T, Nosaka T.

Leukemia. 2009 Dec;23(12):2197-209. doi: 10.1038/leu.2009.177. Epub 2009 Aug 27.

PMID:
19710696
16.

The versatile mixed lineage leukaemia gene MLL and its many associations in leukaemogenesis.

Daser A, Rabbitts TH.

Semin Cancer Biol. 2005 Jun;15(3):175-88. Review.

PMID:
15826832
17.

MLL translocations, histone modifications and leukaemia stem-cell development.

Krivtsov AV, Armstrong SA.

Nat Rev Cancer. 2007 Nov;7(11):823-33. Review.

PMID:
17957188
18.

A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.

DiMartino JF, Miller T, Ayton PM, Landewe T, Hess JL, Cleary ML, Shilatifard A.

Blood. 2000 Dec 1;96(12):3887-93.

19.

Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.

Arai S, Yoshimi A, Shimabe M, Ichikawa M, Nakagawa M, Imai Y, Goyama S, Kurokawa M.

Blood. 2011 Jun 9;117(23):6304-14. doi: 10.1182/blood-2009-07-234310. Epub 2010 Dec 29.

20.

Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9.

So CW, Karsunky H, Wong P, Weissman IL, Cleary ML.

Blood. 2004 Apr 15;103(8):3192-9. Epub 2003 Dec 30.

Supplemental Content

Support Center